MDT

96.57

+0.48%↑

A

137.03

-0.47%↓

VEEV

224.3

+0.29%↑

HQY

92.65

+0.14%↑

PHR.US

16.89

-1.63%↓

MDT

96.57

+0.48%↑

A

137.03

-0.47%↓

VEEV

224.3

+0.29%↑

HQY

92.65

+0.14%↑

PHR.US

16.89

-1.63%↓

MDT

96.57

+0.48%↑

A

137.03

-0.47%↓

VEEV

224.3

+0.29%↑

HQY

92.65

+0.14%↑

PHR.US

16.89

-1.63%↓

MDT

96.57

+0.48%↑

A

137.03

-0.47%↓

VEEV

224.3

+0.29%↑

HQY

92.65

+0.14%↑

PHR.US

16.89

-1.63%↓

MDT

96.57

+0.48%↑

A

137.03

-0.47%↓

VEEV

224.3

+0.29%↑

HQY

92.65

+0.14%↑

PHR.US

16.89

-1.63%↓

Search

Baxter International Inc

Avatud

SektorTervishoid

19.38 1.04

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

19.21

Max

19.43

Põhinäitajad

By Trading Economics

Sissetulek

-173M

-51M

Müük

25M

2.8B

P/E

Sektori keskmine

86.308

78.892

Aktsiakasum

0.69

Dividenditootlus

3.59

Kasumimarginaal

-1.799

Töötajad

38,000

EBITDA

-46M

416M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+17.65% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.59%

2.38%

Järgmine dividendimakse kuupäev

2. jaan 2026

Turustatistika

By TradingEconomics

Turukapital

-2.1B

9.8B

Eelmine avamishind

18.34

Eelmine sulgemishind

19.38

Uudiste sentiment

By Acuity

53%

47%

307 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Baxter International Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. dets 2025, 22:03 UTC

Suurimad hinnamuutused turgudel

Mining Stocks Slip Near the End of Stellar Year

29. dets 2025, 15:57 UTC

Suurimad hinnamuutused turgudel

Praxis Shares Rise on Ulixacaltamide Breakthrough Designation

29. dets 2025, 23:43 UTC

Market Talk

Nikkei May Decline; Yen in Focus -- Market Talk

29. dets 2025, 23:38 UTC

Omandamised, ülevõtmised, äriostud

Manus: Will Continue to Operate From Singapore

29. dets 2025, 23:38 UTC

Omandamised, ülevõtmised, äriostud

Manus: Will Continue to Sell, Operate Product Subscription Service Through App, Website

29. dets 2025, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Meta Platforms: Will Integrate Manus Service Into Products

29. dets 2025, 23:36 UTC

Omandamised, ülevõtmised, äriostud

Meta Platforms: Will Continue to Operate, Sell Manus Service

29. dets 2025, 23:36 UTC

Omandamised, ülevõtmised, äriostud

Meta Platforms: Manus's Talent to Join Team to Deliver General-Purpose Agents Across Consumer, Business Products

29. dets 2025, 23:35 UTC

Omandamised, ülevõtmised, äriostud

Manus to Join Meta Platforms

29. dets 2025, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Origin: Raise Values Kraken at US$8.65 Billion

29. dets 2025, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Origin: Octopus Targeting Kraken Separation by Mid 2026

29. dets 2025, 21:31 UTC

Omandamised, ülevõtmised, äriostud

BlueScope: Rezoning Will Allow for Range of Commercial, Industrial Development Uses

29. dets 2025, 21:31 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Also Says Land Adjacent to Port Kembla Steelworks Rezoned to Special Purpose

29. dets 2025, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Origin's Kraken Stake to Remain at 22.7%

29. dets 2025, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Origin Will Continue to Hold Its 22.7% Interest in Octopus

29. dets 2025, 21:30 UTC

Omandamised, ülevõtmised, äriostud

BlueScope: Guidance Reflects Sustained Strength of Operating Performance in Recent Months

29. dets 2025, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Origin: Additional Interest Offsets Dilution From Raise

29. dets 2025, 21:30 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Doesn't Expect Material Impact on 1H Guidance Range

29. dets 2025, 21:29 UTC

Omandamised, ülevõtmised, äriostud

Origin Waiving Australia Exclusivity to Kraken in Exchange for Additional 1.5% Equity Interest

29. dets 2025, 21:29 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Expects to Complete Property Sale for A$76 Million Consideration

29. dets 2025, 21:29 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Expects to Complete Property Sale in 2H of FY 2026

29. dets 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

BlueScope: Selling Residentially Zoned Land in West Dapto to Large Homebuilder

29. dets 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

Origin: Kraken's Raise Paves Way for Separation From Octopus Energy

29. dets 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

Origin: Kraken to Raise Total US$1 Billion From New, Existing Investors

29. dets 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel Exchanges Contracts for Sale of 33 Hectares of Land in West Dapto

29. dets 2025, 21:27 UTC

Omandamised, ülevõtmised, äriostud

Origin Energy to Invest US$140M in Kraken's Standalone Equity Raise

29. dets 2025, 20:22 UTC

Market Talk

Oil Rebounds As Russia-Ukraine War Seen Continuing -- Market Talk

29. dets 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Futures Rise As Front Month Expires -- Market Talk

29. dets 2025, 20:02 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific--Norfolk Southern Merger Targets Trucking Market Share -- Barrons.com

29. dets 2025, 17:36 UTC

Market Talk

U.S. Natural Gas Inventories Swing to Deficit Vs. 5-Year Average -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Baxter International Inc Prognoos

Hinnasiht

By TipRanks

17.65% tõus

12 kuu keskmine prognoos

Keskmine 22.8 USD  17.65%

Kõrge 36 USD

Madal 15 USD

Põhineb 11 Wall Streeti analüütiku instrumendi Baxter International Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

11 ratings

2

Osta

8

Hoia

1

Müü

Tehniline skoor

By Trading Central

30.475 / 31.345Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

307 / 374 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Baxter International Inc

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
help-icon Live chat